# 506292713 10/07/2020

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6339461

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
STEPHAN BRAUN	10/04/2018

### **RECEIVING PARTY DATA**

Name:	IPSEN INNOVATION S.A.S.	
Street Address:	Z.I. DE COURTABOEUF - 5 AVENUE DU CANADA	
City:	LES ULIS	
State/Country:	FRANCE	
Postal Code:	91940	

### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	16346436

### **CORRESPONDENCE DATA**

#### Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 6174304740821

**Email:** docketing@mcneillbaur.com

Correspondent Name: MCNEILL BAUR PLLC

Address Line 1: 125 CAMBRIDGE PARK DRIVE

Address Line 2: SUITE 301

Address Line 4: CAMBRIDGE, MASSACHUSETTS 02140

ATTORNEY DOCKET NUMBER:	01208-0016-00US
NAME OF SUBMITTER:	RICHARD C. KING
SIGNATURE:	/Richard C. King/
DATE SIGNED:	10/07/2020

## **Total Attachments: 3**

source=2020-06-23\_01208-0016-00US\_Assignment\_Exctd\_Braun-lpsen\_Innovation\_SAS#page1.tif source=2020-06-23\_01208-0016-00US\_Assignment\_Exctd\_Braun-lpsen\_Innovation\_SAS#page2.tif source=2020-06-23\_01208-0016-00US\_Assignment\_Exctd\_Braun-lpsen\_Innovation\_SAS#page3.tif

PATENT 506292713 REEL: 053998 FRAME: 0801

Attorney Docket No.: 245IBL P1 PCT

#### **CONFIRMATORY ASSIGNMENT**

**STEPHAN BRAUN of Zurich, SWITZERLAND** (hereinafter Assignor) confirms that he/she has assigned to **IPSEN INNOVATION S.A.S.**, a company existing under the laws of France and having a place of business at Z.I. de Courtaboeuf – 5 avenue du Canada, Les Ulis, FR 91940, its successors and assigns (hereinafter Assignee), the entire right, title and interest throughout the world in the inventions and discoveries disclosed in:

PCT International Patent Application entitled METHODS FOR TREATING GASTRIC CANCER USING COMBINATION THERAPIES COMPRISING LIPOSOMAL IRINOTECAN AND OXALIPLATIN filed November 1, 2017 and assigned Application Number PCT/GB2017/053293, and its title subsequently amended by the PCT International Searching Authority to TREATING GASTRIC CANCER USING COMBINATION THERAPIES COMPRISING LIPOSOMAL IRINOTECAN, OXALIPLATIN, 5-FLUORURACIL (AND LEUCOVORIN); referred to as the "Application" this assignment including: (1) said Application and any other application, which has been or shall be filed for said inventions in any country of the world, including any and all divisional, continuing, continuing-in-part, or substitute applications based thereon; (2) any and all patents, utility models and design registrations granted for any of said inventions in any country of the world, and all registrations, confirmations, renewals, reexaminations, reissues, Patent Term Extensions and extensions thereof; (3) the right to claim priority based on the filing date of said PCT International Patent Application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; (4) the right to apply in all countries in Assignors' names or in its own name for patents, utility models, design registrations and like rights of exclusion and for inventor(s) certificate(s) for said inventions; and (5) the right to bring, make, oppose, defend and/or appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action whether arising from ownership or otherwise, in respect of any such patent applications, patents or inventions, whether occurring before on or after the date of this assignment.

> PATENT REEL: 053998 FRAME: 0802

Attorney Docket No.: 245IBL P1 PCT

Assignors hereby confirm authorizing and requesting the issuing authority to issue any and all patents claiming said inventions to Assignee or its successors and assigns. Assignors further agree that, upon request and without further compensation, but at no out-of-pocket expense to Assignors and Assignors' successors and/or assigns, will perform such lawful acts and will sign such further applications, assignments, Preliminary Statements and other lawful documents as Assignee may reasonably request to effectuate fully this assignment, including by way of example, but not of limitation, the following acts:

- A. Prompt execution of all lawful oaths, affidavits and/or supplemental oaths required or deemed advisable by Assignee to further the prosecution of any application or applications for letters patent relating to the subject matter of this assignment;
- B. To cooperate to the best of our ability in the execution of all lawful documents, the production of evidence, and the giving of testimony in interference, opposition, nullification or infringement proceedings involving the subject matter of this assignment.

I further agree and desire that this assignment will have effect from the filing date of the above-identified Application.

This confirmatory assignment shall be governed by the laws of France.

[STEPHAN BRAUN]

Date

[WITNESS NAME]

Date

[WITNESS NAME]

4400116141

Date

Attorney Docket No.: 245IBL P1 PCT

The undersigned officer of IPSEN INNOVATION S.A.S. hereby acknowledges the foregoing executed confirmation of the transfer of rights on behalf of IPSEN INNOVATION S.A.S.

IPSEN INNOVATION S.A.S.

Name: Janice M. Klunder Date

Title: VP, Head of Global latellectual
Signed at: Property
Cambridge, MA, USA

**PATENT** REEL: 053998 FRAME: 0804

**RECORDED: 10/07/2020**